Seven Eight Capital, LP Clovis Oncology, Inc. Transaction History

Seven Eight Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$3.93 - $15.35 $274,278 - $1.07 Million	-69,791 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$12.81 - $25.67 $894,022 - $1.79 Million	69,791 New	69,791 $1.04 Million
Q3 2018 Oct 18, 2018	SELL	$29.37 - $49.48 $311,498 - $524,784	-10,606 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$42.06 - $62.4 $54,678 - $81,120	1,300 Added 13.97%	10,606 $482,000
Q1 2018 May 14, 2018	BUY	$50.12 - $67.72 $466,416 - $630,202	9,306 New	9,306 $491,000
Q3 2017 Oct 16, 2017	SELL	$67.17 - $84.81 $598,954 - $756,250	-8,917 Closed	0 $0
Q2 2017 Aug 10, 2017	BUY	N/A	8,917	8,917 $835,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Seven Eight Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Seven Eight Capital, LP with notifications on news.